Search results for "RSU"

showing 10 items of 973 documents

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell glo…

2011

Abstract Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the contr…

AdultMalemedicine.medical_specialtyTime FactorsTransplantation ConditioningAdolescentmedicine.medical_treatmentImmunologyMedizinGraft vs Host DiseaseHematopoietic stem cell transplantationBiochemistryGastroenterologyDisease-Free Survivallaw.inventionRandomized controlled triallawRecurrenceInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceSurvival rateAntilymphocyte SerumImmunosuppression Therapybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryTransplantationSurvival RateGraft-versus-host diseaseMethotrexateHematologic NeoplasmsChronic DiseaseCyclosporineFemalebusinessImmunosuppressive AgentsBlood
researchProduct

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated don…

2009

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic haematopoietic cell transplantation from unrelated donors. Anti-T-cell globulins (ATGs) might lower the incidence of GVHD. We did a prospective, randomised, multicentre, open-label, phase 3 trial to compare standard GVHD prophylaxis with ciclosporin and methotrexate with or without anti-Jurkat ATG-Fresenius (ATG-F).Between May 26, 2003, and Feb 8, 2007, 202 patients with haematological malignancies were centrally randomly assigned using computer-generated centre-stratified block randomisation between treatment groups receiving ciclosporin and methotrexate with or without additional ATG-F. One patie…

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentT-LymphocytesGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterologyInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceProspective StudiesAntilymphocyte Serumbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationMiddle AgedCiclosporinmedicine.diseaseSurvival AnalysisAnti-thymocyte globulinSurgeryTransplantationGraft-versus-host diseaseMethotrexateOncologyHematologic NeoplasmsCyclosporineRegression AnalysisDrug Therapy CombinationFemaleTransplantation ConditioningbusinessImmunosuppressive Agentsmedicine.drugThe Lancet. Oncology
researchProduct

Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation i…

2017

Eighty-one patients with high-risk hematological malignancies received unmanipulated haploidentical stem cell transplants (haploSCT) using the same protocol at four Spanish institutions. The conditioning regimen was thiotepa, busulfan and fludarabine; following bone marrow or peripheral blood infusion. GvHD prophylaxis with high-dose cyclophosphamide on days +3 and +4, and IV tacrolimus from day +5 was administered. 62% were in complete remission, 17% had received previous allogeneic SCT and 44% had a high-very high refined disease risk index. One patient had primary graft failure and three more died before +21. The median days to neutrophil and platelet recoveries were +18 and +23, respect…

AdultMalemedicine.medical_specialtyTransplantation ConditioningCyclophosphamideAdolescentGraft vs Host DiseaseThioTEPAGastroenterologyTacrolimus03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineHumansCyclophosphamideAgedRetrospective StudiesTransplantationbusiness.industryHematologyMiddle Agedmedicine.diseaseTacrolimusFludarabineSurgeryTransplantationsurgical procedures operativemedicine.anatomical_structureGraft-versus-host disease030220 oncology & carcinogenesisHematologic NeoplasmsTransplantation HaploidenticalFemaleBone marrowbusinessBusulfanImmunosuppressive Agents030215 immunologymedicine.drugBone marrow transplantation
researchProduct

Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen

2018

OBJECTIVE Characteristics and risk factors (RFs) of invasive fungal disease (IFD) have been little studied in the setting of umbilical cord blood transplantation (UCBT). METHOD We retrospectively included 205 single-unit myeloablative UCBT recipients with a median follow-up of 64 months. RESULTS Fifty-six episodes of IFD were observed in 48 patients (23%) at a median time of 123 days after stem cell infusion. Invasive mold disease (IMD) occurred in 42 cases, 38 of them (90%) caused by invasive aspergillosis whereas invasive yeast disease (IYD) occurred in 14 cases, most of them due to candidemia (n = 12, 86%). The 5-year cumulative incidence of IFD, IMDs, and IYDs was 24% 19%, and 7%, respe…

AdultMalemedicine.medical_specialtyTransplantation ConditioningMultivariate analysisAdolescentGraft vs Host DiseaseDiseaseAspergillosisSeverity of Illness IndexGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineAnti-Infective AgentsRisk FactorsCause of DeathInternal medicinemedicineHumansPublic Health SurveillanceCumulative incidenceRetrospective Studiesbusiness.industryUmbilical Cord Blood TransplantationIncidenceHematologyGeneral MedicineMiddle Agedmedicine.diseasePatient Outcome AssessmentGraft-versus-host diseaseMycoses030220 oncology & carcinogenesisFemaleCord Blood Stem Cell TransplantationStem cellComplicationbusiness030215 immunologyEuropean Journal of Haematology
researchProduct

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term foll…

2010

Background Allogeneic hematopoietic stem cell transplantation is an effective treatment for patients with poor risk lymphoma, at least in part because of the graft-versus-lymphoma effect. Over the past decade, reduced intensity conditioning regimens have been shown to offer results similar to those of conventional high-dose conditioning regimens but with lower toxicity early after transplantation, especially in patients with chemosensitive disease at transplant. Design and Methods The aim of this study was to analyze the long-term outcome of patients with follicular lymphoma who received an HLA identical sibling allogeneic stem cell transplant with a reduced intensity conditioning regimen w…

AdultMalemedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentFollicular lymphomaHematopoietic stem cell transplantationGastroenterologyreduced intensity conditioningfollicular lymphomaallogeneic stem cell transplantationInternal medicinemedicinegraft-versus-host diseaseHumansTransplantation HomologousLymphoma FollicularSurvival ratebusiness.industryHistocompatibility TestingSiblingsHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseSurgeryFludarabineSurvival RateTransplantationTreatment OutcomeGraft-versus-host diseaseFemaleOriginal ArticleTransplantation ConditioningbusinessProgressive diseaseFollow-Up Studiesmedicine.drugHLA identical sibling donor
researchProduct

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II

2010

Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is an X-linked, recessive, lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase. It has multisystemic involvement, with manifestations in the brain, upper respiratory tract, heart, abdomen, joints and bones. Bone involvement leads to decreased growth velocity and short stature in nearly all patients. A therapeutic option for patients with MPS II is enzyme replacement therapy (ERT) with idursulfase (Elaprase®). We compared annual growth rates before and during ERT in 18 patients from Mainz, Germany, and Manchester, UK. Group 1 included nine patients who started ERT before 10 years of age; group 2 contained nine patie…

AdultMalemedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesAdolescentIdursulfaseIduronate SulfatasePlaceboShort staturePlacebosYoung AdultChild DevelopmentClinical Trials Phase II as TopicmedicineGeneticsHumansGenetics(clinical)Enzyme Replacement TherapyMucopolysaccharidosis type IIYoung adultGrowth ChartsChildGenetics (clinical)Mucopolysaccharidosis IIbusiness.industrynutritional and metabolic diseasesHunter syndromeEnzyme replacement therapymedicine.diseaseBody HeightSurgerymedicine.anatomical_structureClinical Trials Phase III as TopicAbdomenOriginal Articlemedicine.symptombusinessmedicine.drugJournal of Inherited Metabolic Disease
researchProduct

Mild androgen phenotypes.

2006

Mild androgen phenotypes are found in 30-40% of patients referred to an endocrine clinic because of suspected hyperandrogenic syndrome. These disorders are characterized by clinical or biological signs of hyperandrogenism in women with normal ovulatory menstrual cycles. Three main mild androgen disorders may be distinguished: ovulatory polycystic ovarian syndrome (PCOS), idiopathic hyperandrogenism, and idiopathic hirsutism. Ovulatory PCOS includes ovulatory hyperandrogenic patients presenting with polycystic ovaries. Using ESHRE/ASRM criteria for diagnosis of PCOS, this disorder is now part of PCOS spectrum. While in vivo and in vitro studies have confirmed the similarities between the two…

AdultOvulationRiskmedicine.medical_specialtyHirsutismendocrine system diseasesmedicine.drug_classEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectEndocrinologyInsulin resistanceInternal medicinemedicineEndocrine systemHumansOvulationhirsutismmedia_commonUltrasonographybusiness.industryHyperandrogenismOvarymedicine.diseaseAndrogenPhenotypePolycystic ovaryEndocrinologyPhenotypeCardiovascular DiseasesFemalebusinessHyperandrogenismPolycystic Ovary SyndromeBest practiceresearch. Clinical endocrinologymetabolism
researchProduct

Prevalence of idiopathic hirsutism.

1998

Objective: To evaluate the prevalence of idiopathic hirsutism in a large population of hirsute women. Design: 588 hirsute women (mean age 24 6 1, range 15‐36 years) were evaluated as outpatients at the Department of Endocrinology of the University of Palermo, Italy. The diagnosis of idiopathic hirsutism was established in hirsute patients presenting regular ovulatory menstrual cycles and normal serum androgen levels (total testosterone, unbound testosterone and dehydroepiandrosterone sulfate). Methods: Hirsutism was calculated by the Ferriman-Gallwey-Lorenzo index. Serum androgens were evaluated in the follicular phase (days 5 or 6) and normal androgen ranges were calculated as the mean 6 2…

AdultOvulationmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectPopulationLuteal phasechemistry.chemical_compoundEndocrinologyDehydroepiandrosterone sulfateInternal medicineFollicular phasemedicineHumansTestosteroneeducationOvulationTestosteronehirsutismProgesteronemedia_commoneducation.field_of_studybusiness.industryDehydroepiandrosterone SulfateGeneral Medicinemedicine.diseaseAndrogenMenstruationEndocrinologychemistryAndrogensFemalebusinessEuropean journal of endocrinology
researchProduct

Multilayer amniotic membrane transplantation in severe ocular graft versus host disease

2001

To clarify the usefulness of multilayer amniotic membrane transplantation in an unusual case of calcareous corneal degeneration in a patient with graft-versus-host disease.A 20-year-old Caucasian woman had bilateral calcareous corneal degeneration of one year of evolution, secondary to graft-versus-host disease. Treatment for both eyes with topical steroids and antibiotic ointment was not successful. Right eye had a spontaneous corneal perforation, and a three-layer circle amniotic membrane graft was applied to the whole cornea.During a follow-up period of 20 months we observed stability of the corneal epithelium and stroma. The amniotic membrane-covered area showed rapid epithelization, re…

AdultPathologymedicine.medical_specialtyEye diseaseCorneal StromaVisual AcuityGraft vs Host DiseaseCorneal Diseases03 medical and health sciences0302 clinical medicineImmunopathologyMedicineHumansAmnionUnusual caseAmnionRupture Spontaneousbusiness.industryEpithelium CornealGeneral Medicinemedicine.diseaseTransplantationOphthalmologysurgical procedures operativeMembraneGraft-versus-host diseasemedicine.anatomical_structure030221 ophthalmology & optometryFemaleBone marrowbusiness030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey.

2011

Purpose: To use the Hunter Outcome Survey, an international database, to assess the safety and effectiveness of enzyme replacement therapy with idursulfase in patients with Hunter syndrome who started treatment before 6 years of age. Methods: The study population included all patients enrolled in the Hunter Outcome Survey who started idursulfase infusions (0.5 mg/kg every other week) before 6 years of age and who had at least one follow-up examination recorded. Results: The study population included 124 patients, younger than 6 years, who had a mean age at start of idursulfase of 3.6 ± 1.6 years (mean ± SD). The mean duration of treatment was 22.9 ± 14.6 months. A total of 69 infusion-relat…

AdultPediatricsmedicine.medical_specialtyAdolescentDatabases FactualIdursulfaseUrineIduronate Sulfatasechemistry.chemical_compoundYoung AdultInternational databaseMedicineHumansEnzyme Replacement TherapyYoung adultChildInfusions IntravenousGenetics (clinical)GlycosaminoglycansMucopolysaccharidosis IICreatinineClinical Trials as Topicbusiness.industryData CollectionInfantHunter syndromeEnzyme replacement therapymedicine.diseaseTreatment OutcomechemistryChild PreschoolPopulation studybusinessmedicine.drugGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct